Results 251 to 260 of about 528,761 (298)

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Low and High Pressor Doses of Ang II Lead to Two Distinct Phenotypes of Hypertensive Heart Disease in Mice. [PDF]

APMIS
Törmä D, Suoranta T, Rinta-Harri M, Hytönen J, Ylä-Herttuala S, Ruotsalainen AK.   +5 more
europepmc   +1 more source

SNX16 aggravates AngII-induced cardiac hypertrophy in mice via EGFR transactivation. [PDF]

Commun Biol
Xie L, Wen K, Yu GH, Li X, Zeng YY, Qiao XH, Lu BQ, Chen L, Wang XL, He J, Lin YJ, Ren XY, Wu X, Yang QK, Hu LL, Ji Y, Xin HB, Deng KY.   +17 more
europepmc   +1 more source

CHARACTERIZING AQP9: A REGULATOR OF EPIPHYSEAL PLATE CHONDROCYTE PROLIFERATION, HYPERTROPHY, AND LONG BONE GROWTH

, 2018
Pontius Tang
openalex   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Novel Cut-Off Values of Precordial Voltage Indexes for Light Chain Amyloidosis Cardiomyopathy in a Chinese Population. [PDF]

J Cardiovasc Dev Dis
Pan R, Zhuang S, Wang Z, Ren X, Tian Z, Zhang S.   +5 more
europepmc   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Modeling the interplay of sex hormones in cardiac hypertrophic signaling. [PDF]

PLoS Comput Biol
Lakshmikanthan A, Kay M, Oomen PJA.
europepmc   +1 more source

Should all patients be offered liver venous deprivation for insufficient future liver remnant hypertrophy prior to major hepatectomy? [PDF]

Hepatobiliary Surg Nutr
Gamboa AC, Newhook TE.
europepmc   +1 more source